

# Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/MD11909E255EN.html>

Date: September 2018

Pages: 30

Price: US\$ 3,500.00 (Single User License)

ID: MD11909E255EN

## Abstracts

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2018

### SUMMARY

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Melanin-concentrating hormone receptor 1 also known as MCH1 is one of the human melanin-concentrating hormone receptors. MCH1 is a target for the orexigenic peptide leptin, which supports a role for MCH receptors in the control of food intake and energy expenditure. MCH1 helps in regulation of stress, anxiety and depression.

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) pipeline Target constitutes close to 5 molecules. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Metabolic Disorders and Gastrointestinal which include indications Obesity and Non-Alcoholic Steatohepatitis (NASH).

The latest report Melanin Concentrating Hormone Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like

Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1)

The report reviews Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Overview

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Companies

Involved in Therapeutics Development

AstraZeneca Plc

Boehringer Ingelheim GmbH

ConSynance Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Drug

Profiles

AZ-13483342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-3857 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-186908 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSTI-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize MCHR1 for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Dormant Products

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Discontinued Products

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Product Development Milestones

Featured News & Press Releases

Apr 25, 2018: ConSynance Presents NASH Results

Oct 03, 2011: AMRI Presents Final Phase I Clinical Studies Results Of Obesity Compound At 29th Annual Scientific Meeting Of Obesity Society

May 31, 2011: AMRI Announces Successful Completion Of Phase I Clinical Study Of Obesity Compound

May 19, 2011: AMRI To Present Phase I Clinical Results Of Obesity Compound At European Congress On Obesity

Jul 21, 2010: AMRI Initiates Phase I Study Of ALB-127158(a) For Treatment Of Obesity

Jun 02, 2009: AMRI Advances New Obesity Drug MCH-1 Receptor Antagonist Toward IND Submission

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Boehringer Ingelheim GmbH, H2 2018

Pipeline by ConSynance Therapeutics Inc, H2 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

### COMPANIES MENTIONED

AstraZeneca Plc

Boehringer Ingelheim GmbH

ConSynance Therapeutics Inc

Takeda Pharmaceutical Co Ltd



## I would like to order

Product name: Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/MD11909E255EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MD11909E255EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970